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PHARMACOLOGICAL TARGETING OF THE AUTOPHAGY PATHWAY IN PANCREATIC 
DUCTAL ADENOCARCINOMA CELLS 
JAMES COLE PARZICK 
ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating of all 
cancers. It is responsible for only 3% of cancer cases annually but is the cause of over 7% 
of cancer related deaths. Despite the prevalence of this diseases there remains a 
scarcity of rational targeted chemotherapies.  
The most frequently observed driver mutation in PDAC is in the KRAS gene. KRAS 
is a GTPase protein in the RAS-RAF-MEK-ERK (MAPK) pathway. This pathway regulates 
vital functions necessary for cell proliferation, differentiation, and survival. 
Unfortunately, efforts to pharmacologically inhibit KRAS have been unsuccessful.  
PDAC can be subdivided into two classes: KRAS-dependent and KRAS-
independent. KRAS-dependent cell lines acquire numerous genetic mutations yet still 
require sustained activity of the KRAS protein to survive. These two subtypes of PDAC 
have distinct genetic and morphological features. One such difference is expression of 
the Spleen tyrosine kinase (Syk), which is expressed at higher levels in KRAS-dependent 
cell lines.  
Syk is a non-receptor tyrosine kinase that functions downstream of KRAS and is 
an upstream activator of mTORC1. mTORC1 activity is associated with anabolic 
vi 
processes such as protein and lipid synthesis, while its suppression causes activation of 
the catabolic autophagy pathway. Like KRAS, mTORC1 has proven to be a poor drug 
target in clinical studies. This issue necessitates the discovery of other therapeutic 
targets in the pathway. Inhibiting Syk with the inhibitor PRT062607 (Syki) results in 
decreased mTORC1 activity, increased autophagy, and cell death.  
In this study we aim to identify compounds that act synergistically with Syki to 
produce an enhanced therapeutic effect. Synergy can be summarized as a 
combinational effect greater than the expected additive effect of each agent acting 
individually. We evaluated the effects of various drug combinations on cell viability and 
studied the impact of these compounds on the autophagy pathway.  
We found a synergistic killing effect when cells were treated with Syki and the 
iron-chelating agent Nocardimicin F (NCF). Live cell imaging assays showed that NCF is a 
strong activator of the autophagy pathway. Western Blot data suggest that NCF 
activates the autophagy pathway through a mechanism independent of mTORC1 
suppression. Furthermore, our data suggest that the cytotoxicity of Nocardimicin does 
not result from induction of apoptosis. We hypothesize that cell death proceeds via an 
autophagy dependent mechanism called autosis. Autosis is a poorly understood process, 
however, is known to be dependent on the Na+/K+-ATPase. Our findings provide 
rationale for further study of the effects of iron-chelating compounds in PDAC and 
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Prevalence of Pancreatic Cancer  
In 2020 roughly 1.8 million Americans were diagnosed with cancer. In the same 
time span over 600,000 Americans were killed by these illnesses, making cancer the 
second leading cause of death in the country behind heart disease. According to the 
NIH, the five-year survival rate for all cancers combined has increased from around 35% 
in the 1960’s up to 70% in 2020[1]. Sadly, the five-year survival rate for those diagnosed 
with pancreatic cancer has not improved and remains just under 6%. While pancreatic 
cancer accounts for 3% of all annual cancer cases, it is the cause of 7% of all deaths. This 
is in part due to the fact that most patients experience few symptoms during early 
stages of pancreatic cancer progression. As a result, the vast majority (~85%) of people 
with this disease have inoperable or metastatic cancer when first diagnosed[2]. However, 
silent progression cannot be the sole reason for the terrible five-year prognosis, as the 
survival rate only increases 10% for patients with resectable tumors[2]. Unlike, for 
example, HER2+ breast cancer for which there are extremely targeted 
chemotherapeutics, such as tamoxifen, the drugs used to treat pancreatic cancer are 
general cytotoxic agents such as 5-fluorouracil[3]. The only approved targeted therapies 
for pancreatic cancer are the EGFR inhibitor erlotinib and the PARP inhibitor olarparib, 
which have limited therapeutic efficacy. It is vital that we study the underlying cellular 
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mechanisms of pancreatic cancer so that we can discover key vulnerabilities for the 
design of rational targeted therapies to treat this disease.  
 
Genetic Basis of Pancreatic Cancer  
 The majority of pancreatic cancers arise from the epithelial cells of the 
pancreatic ducts and referred to as pancreatic ductal adenocarcinomas (PDAC). Under 
normal conditions these cells contribute to the exocrine function of the pancreas by 
producing digestive enzymes and bicarbonate, which is needed to neutralize the pH of 
chyme entering the duodenum. The pancreas also consists of structures called islets of 
Langerhans which are involved in the organs endocrine function. The primary role of the 
endocrine pancreas is to secrete insulin and glucagon, thus maintaining glucose 
homeostasis[4]. While neuroendocrine tumors can arise from islet cells, they are far less 
common than PDAC and are not the focus of this dissertation.   
PDAC is driven by four common gene mutations: KRAS, CDKN2A, TP53, and 
SMAD4[2]. CDKN2A, TP53, and SMAD4 are tumor suppressor genes. KRAS mutations are 
oncogenic, and present in over 90% of PDAC. Moreover, mutant KRAS expression is 
sufficient to induce tumor growth in murine models.  
KRAS is a proto-oncogene that encodes a small GTPase protein. When bound to 
guanosine triphosphate (GTP) the protein is in the active state in contrast to the GDP-
bound inactive state[5]. KRAS GTP binding and activation is mediated by membrane-
associated receptor tyrosine kinases (RTKs). RTKs recruit GEF’s (guanine nucleotide 
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exchange factors) to the cell membrane, which catalyze the exchange of GDP for GTP. 
GTP-bound KRAS undergoes a conformational switch allowing for interaction with 
downstream targets that promote cell growth, proliferation, and metabolism. While 
KRAS has intrinsic GTPase capability, the rate of GTP hydrolysis is accelerated through 
interaction with a group of proteins known as GAPs (GTPase Activating Proteins). 
Hydrolysis of GTP to renders KRAS inactive. Many GAPs, such as NF1, are tumor 
suppressor genes. Mutations at codon G12, G13, and Q61 have been shown to interfere 
with the proteins intrinsic GTPase activity or interaction with associated GAPs thereby 
conferring it constitutive activation[5]. Activating KRAS mutations cause continuous flux 
through the cell cycle and dysregulation of various cellular processes, including 
resistance to apoptotic cell death and suppression of autophagy. 
 
KRAS Signaling 
 When a ligand, such as Epidermal Growth Factor (EGF), binds to its associated 
RTK on the extracellular membrane the receptors dimerize resulting in activation of the 
RTK kinase domain and tyrosine residue transphosphorylation. Docking proteins, for 
example GRB2, contain SH2 domains that bind the phosphotyrosine residues and recruit 
GEF’s to the cell membrane[5,6]. Once active the GEF’s catalyze the exchange of GDP for 
GTP on KRAS causing a conformational change activating the protein. At this stage KRAS 





 One of the most important pathways activated by KRAS is the extracellular 
signal-regulated kinase (ERK) pathway also known as mitogen-activated protein kinase 
(MAPK) pathway [7]. KRAS-GTP associates with a serine/threonine kinase called RAF. 
Activated RAF phosphorylates MEK, which in turn phosphorylates and activates ERK . 
ERK has many downstream targets most of which are associated with progression 
through the cell cycle, cell survival, differentiation and protein translation. One notable 
target of ERK are the Cyclin D/CDK4/6 complex proteins, which control the checkpoint 
from G1 into S phase of the cell cycle[7,5].  
Another important target of ERK is the tuberous sclerosis protein complex 
(TSC1/2)[8]. The TSC1-TSC2 complex is sensitive to a number of different signals and can 
be influenced by several cellular pathways. The TSC is inactivated when phosphorylated 
by ERK and other kinases[7,9]. Active TSC2 serves as a GAP for the protein Rheb. TSC1 
does not have a GAP function, however, it appears to prevent the degradation of TSC2. 
When Rheb is bound to GTP it is an activator of the mammalian target of rapamycin 
complex 1 (mTORC1), which functions as a kinase to phosphorylate proteins involved in 
cap-dependent translation and autophagy[9]. TSC acts as a negative regulator of Rheb. 







 Phosphoinositide 3-kinase (PI3K) is a lipid kinase which is also activated by KRAS. 
KRAS-GTP recruits PI3K to the cytoplasmic side of the cell membrane and activates it via 
interaction with PI3K p110 catalytic subunit, which contains a RAS association 
domain[10]. Activated PI3K phosphorylates the membrane lipid phosphatidylinositol-4,5-
biphosphate (PIP2 ) yielding phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 acts as a 
second messenger and is able to interact with proteins via pleckstrin homology domains 
(PH domains)[10].  
The protein kinase Akt remains in the inactive state in the cytosol of the cell. 
When PI3K produces PIP3 in the plasma membrane, Akt is recruited via its PH domain. 
However, this interaction is not sufficient to activate Akt. It must first be phosphorylated 
by two other kinases that are indirectly activated by PI3K. The first is Phosphoinositide-
dependent kinase 1 (PDK1), which phosphorylates Akt at T308[11]. The second kinase is 
part of mTORC2, which phosphorylates Akt at S473. The mTOR kinase itself does not 
contain a PH domain. The rise in PIP3 at the cell membrane is sensed by the PH domain 
of SIN1 which is part of the mTOR complex 2. Once fully activated, Akt has a number of 
downstream pro-survival targets[12].  
One way in which Akt promotes survival is through phosphorylation of murine 
double minute 2 (MDM2). Phosphorylation of MDM2 increases its translocation from 
the cytoplasm to the nucleus. In the nucleus MDM2 promotes proteolytic degradation 
of the transcription factor p53[13]. P53, often referred to as the guardian of the genome, 
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is responsible for monitoring the integrity of DNA, controlling flux through the G1 
checkpoint, and causing apoptosis through translation of proapoptotic Bcl-family genes 
PUMA and NOXA. MDM2 also upregulates the expression of X-linked inhibitor of 
apoptosis protein (XIAP), a protein capable of directly binding and inhibiting 
caspases[14,15]. MDM2 prevents apoptosis by both suppressing pro-apoptotic genes and 
inducing anti-apoptotic genes.  Similarly, Akt phosphorylates the Forkhead box (FOXO) 
transcription factors preventing its translocation to the nucleus. Like p53, the FOXO 
transcription factors are involved in cell cycle arrest, metabolism, and induction of 
apoptosis[16]. Through these mechanisms Akt activity prevents apoptosis and promotes 
progression through the cell cycle.  
Akt exerts control over mTORC1 via the same mechanism as ERK: 
phosphorylation of TSC2[12]. As mentioned before, phosphorylation of TSC2 relieves 
inhibition of Rheb and therefore activates mTORC1. In vitro studies have shown that 
phosphorylation does not interfere with TSC2’s GAP function toward Rheb, but rather 
creates a binding site for 14-3-3 proteins which prevent TSC2 binding to Rheb. 
 
mTORC1 
 Mammalian target of rapamycin (mTOR) is a serine/threonine kinase, which is 
regulated by two distinct multimeric protein complexes; mTORC1 and mTORC2. 
mTORC1  positively regulators of anabolic cellular processes such as protein translation 
and lipid synthesis while negatively regulating catabolic processes such as autophagy[17]. 
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The complex is sensitive to growth factors, cellular energy level, hypoxia, and amino acid 
supply. mTORC1 is composed of the mTOR kinase, mammalian lethal with SEC13 protein 
8 (MLST8), proline-rich AKT1 substrate (PRAS40), regulatory-associated protein of mTOR 
(Raptor), and DEP domain-containing mTOR interacting protein (DEPTOR). Raptor 
facilitates the kinase function of mTOR through binding of its substrates[17].  
mTORC1 is sensitive to the energy level of the cell through the action of the 
AMP-activated protein kinase (AMPK)[8]. AMPK is allosterically activated by high 
AMP/ATP and ADP/ATP ratio within the cell. When these ratios are high, the cell is in an 
energy depleted state and will ideally switch from an anabolic to catabolic metabolism. 
AMPK phosphorylates Raptor directly, thereby blocking its ability to recruit substrates of 
mTORC1. It further inhibits mTORC1 through phosphorylation of TSC2. It was previously 
mentioned that phosphorylation of TSC2 by ERK or Akt led to its inactivation and 
subsequent activation of mTORC1 via Rheb[12]. However, when phosphorylated by 
AMPK at T1227 and S1345 TSC2 becomes an active GAP, thus accelerating the rate of 
GTP hydrolysis by Rheb, resulting in suppression of mTORC1[8]. 
Under normoxic conditions the protein hypoxia inducible factor 1ɑ (HIF1ɑ) is 
hydroxylated at various proline residues, allowing it to be recognized by VHL E3 
ubiquitin ligases and is subsequently degraded at the proteasome[18]. Under hypoxic 
conditions the HIF prolyl-hydroxylases are inhibited and HIF1ɑ is not degraded.  HIF1ɑ is 
a transcription factor for genes that help the cell survive in low oxygen conditions. One 
of these genes encodes for a protein called regulated in development and DNA damage 
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1 (REDD1)[19]. REDD1 binds to TSC2 and prevents association with 14-3-3 proteins, 
thereby relieving inhibition of TSC2leading to inactivation of Rheb. Therefore, hypoxia 
mediated induction of HIF1ɑ, through the action of REDD1 on TSC2 leads to suppression 
of mTORC1.   
HIF1ɑ, AMPK, Erk, and Akt exert control over mTORC1 through TSC2. Amino acid 
supply influences the activity of mTORC1 through a mechanism independent of TSC2[20]. 
The activation of mTORC1 by amino acid supply is initiated by a group of proteins called 
Ras-related GTP binding GTPases (Rag). RAGA and RAGB form a heterodimer which is 
active in the GTP bound state, and RAGC and RAGD form a heterodimer that is active in 
the GDP bound state. Rag proteins are associated with the lysosomal surface via the 
pentameric Ragulator Complex. The Ragulator complex contains palmitoyl and myristyl 
lipid anchors which tether it to the lysosome[21]. The presence of amino acids causes the 
RAG heterodimers to shift into their respective active states. Activated RAG 
heterodimers bind to Raptor and thus recruit mTORC1 to the surface of the lysosome 
where it is activated by Rheb. Under nutrient poor conditions (low amino acid supply) 
mTORC1 is diffuse and inactive in the cytoplasm.  
 
Downstream Targets of mTORC1  
 To promote the cellular growth and proliferation mTORC1 targets proteins 
associated with the synthesis of lipids, nucleotides, and proteins, while preventing 
catabolism through suppression of autophagy.  
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 mTORC1 increases protein translation through activation of two proteins: p70S6 
kinase 1 (S6K1) and eIF4E binding protein (4EBP)[17,22]. Eukaryotic translation initiation 
factor 4E (eIF4E) is a necessary component of the protein translation initiation complex. 
eIF4E complexes with factor 4A and 4G and binds the 5’ cap of mRNA. At this point 
factor 4B and helicase join the initiation complex, causing the recruitment of the 40S 
small ribosomal subunit and the beginning of protein translation. 4EBP inhibits protein 
translation by binding eIF4E and preventing the formation of the initiation complex. 
When activated, mTORC1 phosphorylates 4EBP at various sites causing it to release 
eIF4E, thus allowing initiation of protein synthesis. mTORC1 further activates translation 
by phosphorylating S6K1 at thr389[17,22]. This allows PDK1 to recognize and 
phosphorylate S6K1 causing it to be fully activated. S6K1 phosphorylates ribosomal 
subunit S6 and eIF4B resulting in activation of translation. Active S6K1 can also bind the 
SKAR scaffold protein which is a part of the exon junction complex (EJC)[23]. When S6K1 
is present at the EJC it enhances the translation of spliced mRNAs. Lastly, S6K1 can 
phosphorylate programmed cell death protein 4 (PDCD4), which causes PDCD4 to be 
ubiquitinated and degraded. Among other functions, PDCD4 inhibits eIF4B and thus 






mTORC1 increases synthesis of lipids and sterols through interaction with a 
transcription factor called sterol regulatory element-binding protein (SREBP)[24,25]. This 
transcription factor enhances translation of proteins needed for uptake and 
biosynthesis of lipids and cholesterol. SREBP is ordinarily embedded in the membrane of 
the endoplasmic reticulum (ER). When intracellular levels of cholesterol are low, SREBP 
is trafficked to the Golgi where its N-terminal domain is cleaved and subsequently 
translocated to the nucleus where it acts as a transcription factor. While the exact 
pathway remains unclear, it is known that mTORC1 enhances SREBP N-terminus 
translocation to the nucleus through an S6K1-dependent mechanism. mTORC1 has also 
been shown to directly phosphorylate Lipin1, an inhibitor of SREBP, resulting in 
disinhibition of the transcription factor[25].  
Figure 1: Erk and PI3K Control of mTORC1 
The figure above shows how the Erk, PI3K, and several other players control 
activation of mTORC1 through inhibition of the TSC1/2 complex. The figure also 




 In addition to promoting various anabolic pathways, mTORC1 is responsible for 
suppression of catabolic pathways, most notably autophagy. The details of autophagy 
will be discussed in detail in the next section. mTORC1 phosphorylates Unc-51 like 
autophagy activating kinase 1 (ULK1), which is a key regulator of autophagy[26]. This 
prevents AMPK from activating ULK1 resulting in suppression of the autophagy pathway 
when mTORC1 is active. mTORC1 further hinders autophagy by phosphorylating and 
inhibiting translocation of the MiT/TFE family of transcription factors leading to 
transcription and translation of  proteins associated with lysosome biosynthesis[22,26].  
 
Autophagy 
 Autophagy is the process through which cells break down their own organelles 
and proteins to recycle the amino acid building blocks for de novo synthesis or for 
energy. Autophagy was originally believed to be strictly a pro-survival mechanism during 
times of nutrient deprivation. It has recently been shown to be an important 
homeostatic process in non-starved cells, replacing cellular machinery and 
protecting against harmful accumulation of misfolded protein aggregates. Three distinct 
types of autophagy have been categorized: microautophagy, chaperone-mediated 
autophagy (CMA), and macroautophagy[26].  
 Microautophagy involves the uptake of molecules directly from the cytosol by 
the lysosome through membrane invagination. In CMA, proteins destined for 
degradation are bound to Hsc family chaperon proteins and translocated into the 
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lysosome through lysosomal membrane receptors. The mechanism of macroautophagy 
will be discussed in detail below, and for the remainder of this investigation the term 
‘autophagy’ will refer specifically to macroautophagy.   
 Macroautophagy begins with the formation of an immature double membrane 
structure called a phagophore. It is believed that the phagophore is formed from the ER 
membrane, but studies have been unable to reject the possibility of de novo synthesis. 
The mechanism of phagophore formation is not fully understood, however, it is clear 
that it requires the activity of ULK-1. When mTORC1 is inhibited and AMPK is active, 
ULK-1 is phosphorylated and becomes active. Activated ULK-1 phosphorylates Beclin-1 
which forms a complex with various proteins including vesicular sorting protein 34 
(Vsp34) which is a class III PI3K. Vsp34 causes the conversion of phosphatidylinositol to 
phosphatidylinositol triphosphate (PI3P) on the phagophore membrane. PI3P is needed 
as a docking site for various Atg proteins that are associated with phagophore 
elongation and maturation. The described mechanism for the formation of the 
phagophore is inhibited when a protein called B-cell Lymphoma 2 (Bcl-2) binds Beclin-1 
and prevents its association with Vsp34. In response to low nutrients, and various other 
cellular signals, c-Jun N-terminal Kinase 1 (JNK1) phosphorylates Bcl-2 causing it to 
dissociate from Beclin-1, thus disinhibiting the formation of the phagophore[26].  
At this stage, a series of ATP-dependent activation events results in the 
association of Atg5-Atg12-Atg16L with the growing phagophore. This complex activates 
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Atg3, which is needed to recruit microtubule-associated protein light chain 3 (LC3B) to 
the surface of the phagophore[26].  
The full LC3B protein is found diffuse within the cytosol. When autophagy is 
activated, LC3B is cleaved by the cysteine protease Atg4 to form LC3B-I. LC3B-I is then 
conjugated to phosphatidylethanolamine (PE) by Atg3, resulting in the formation of 
LC3B-II. LC3B-II is needed for cargo selection and fusion with the lysosome, making it a 
reliable biomarker for autophagy. Lipidated LC3B results in closure of the phagophore, 
creating a spherical structure called the autophagosome. Through the action of Snap 
Receptor proteins (SNARE’s) the autophagosome fuses with the lysosome resulting in 
the formation of the autolysosome. The LC3 proteins found on the inside of the 
autolysosome are degraded along with the contents of the vesicle, while the LC3 on the 
exterior surface are cleaved off by Atg4. The resulting recycled amino acids are exported 











Autophagy and Cancer 
The role of autophagy as a tumor-suppressing or tumor-promoting process 
remains unclear and is likely context dependent. Autophagy is responsible for degrading 
damaged organelles such as mitochondria. Damaged mitochondria can produce large 
amounts of reactive oxygen species (ROS) which are known to cause DNA damage and 
may promote cancer progression. In this context autophagy can be thought of as a 
tumor-suppressive mechanism.  
The internal environment of solid tumors tends to be hypoxic and nutrient 
deprived due to the high rate of cell proliferation and lack of adequate blood supply[27]. 
Figure 2: Summary of Autolysosome Formation 
 
 Part (a) of this figure shows the role of Beclin1 in regulating formation of the 
phagophore. (b) shows the conjugation of Atg 5-Atg 12. (c) shows the role of Atg 3, 
Atg 4, and Atg 7 in LC3 processing. (d) illustrates the engulfment of cargo by the 
phagophore resulting in maturation to an autophagosome. (e) depicts fusion of the 
autophagosome with the lysosome resulting in formation of the autolysosome. 
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In this context autophagy promotes tumor growth by recycling intracellular components 
to me the metabolic demands of these rapidly dividing cells.  
Almost all chemotherapies are associated with initial (de novo) or acquired drug 
resistance[28]. Autophagy can promote survival under conditions of cellular stress 
induced by chemotherapeutic agents. Essentially, autophagy extends the life span of a 
cancer cell and gives it more time to acquire mutations that confer drug resistance29. 
Autophagy is thought to be one of the most prominent mechanisms by which cancer 
cells acquire drug resistance. Inhibition of autophagy has been shown to re-sensitize 
various types of cancer to chemotherapeutic agents against which they had previously 
acquired resistance[30,31].  
 
KRAS-dependency  
 Cancer cells acquire numerous genetic insults and tend to continue to 
accumulate mutations the longer they survive. In some cases, however, 
inactivation/inhibition of a dominant driver oncogene is sufficient to block the growth, 
proliferation, or survival of the cancer cells. In these instances, the cancer is referred to 
as oncogene-addicted or dependent[32]. RNA interference studies have been used to 
suppress expression of KRAS in various PDAC cell lines[33,34]. The results of these 
experiments indicate that PDACs can be classified as KRAS-dependent and KRAS-
independent. KRAS-addicted pancreatic cancer cells have an epithelial morphology, 
expressing high levels of E-cadherin on the extracellular membrane. E-cadherin is a cell 
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adhesion protein that is a canonical marker of epithelial morphology. In contrast, KRAS-
independent PDAC has little to no E-cadherin expression, and instead has high levels of 
vimentin[33]. Vimentin is a type III intermediate filament protein that is typically 
expressed in mesenchymal cells. For this reason, vimentin expression is used as a 
marker for epithelial-to-mesenchymal transition (EMT). KRAS-dependent PDAC express 
significantly higher levels of Spleen tyrosine kinase (SYK), integrin beta6, and RON RTK 
than KRAS-independent cell lines[33]. Suppression of these genes induced EMT and 
subsequent cell death in KRAS-addicted cells. For this reason, SYK, and the other 
proteins mentioned, represent possible therapeutic targets for KRAS-dependent PDAC.  
 
Spleen Tyrosine Kinase (SYK)  
 Spleen Tyrosine Kinase (SYK) is a cytosolic non-receptor tyrosine kinase. SYK is 
best known for its role in innate and adaptive immune responses. At the N-terminus, 
Syk contains two SRC homology 2 (SH2) domains separated by a part of the protein 
called interdomain A[35]. The SH2 tandem is connected to the C-terminal kinase domain 
by interdomain B. Interaction between interdomain A and B causes Syk to remain in a 
closed conformation that blocks its kinase activity.  
In hematopoietic cells, Syk is activated through various mechanisms. Upon 
binding a ligand, immune receptors associate with ITAMs, which are phosphorylated on 
the intracellular domain by Src family kinases. The SH2 domains of Syk bind the dual 
phosphorylated ITAM causing a conformational change that relieves Syk of its 
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autoinhibition. SRC family kinases can directly phosphorylate tyrosine residues of 
interdomains A and B preventing their interaction, resulting in activation of Syk kinase 
function[36]. The upstream mechanism of Syk activation in pancreatic epithelial cells 
remains to be elucidated.  
Activated Syk recruits and phosphorylates numerous substrates with SH2 
domains which activate pro-growth and proliferation pathways. The most studied 
targets are phospholipase C𝛄 (PLC𝛄), which is a regulatory subunit of PI3K, and SH2 
domain-containing leukocyte proteins (SLP). Although the mechanism remains unclear, 
Syk has been shown to activate the mTOR pathway possibly through the PI3K/Akt 
pathway and or the RAS/ERK pathway[37]. As mentioned before, mTORC1 (and by 
extension Syk) suppresses activation of the autophagy pathway. Conversely, inhibition 
of Syk has been shown to increase autophagy[38]. 
 
Syk and Cancer 
 The role of Syk as a tumor suppressor or tumor promoter appears to be context 
dependent. Studies of various hematological cancers, such as B-cell lymphomas, have 
shown that silencing Syk causes apoptosis and tumor suppression[39].  
As previously stated, Syk is highly expressed in KRAS-dependent epithelial PDAC 
cells, where it acts as a tumor promoter through activation of pathways associated with 
growth and proliferation, such as mTORC1[33]. Syk knockdown causes induction of 
apoptosis in KRAS-addicted PDAC cells[33,39]. In contrast, KRAS-independent PDAC 
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cells have low levels of Syk expression and display a less differentiated/mesenchymal 
phenotype. Experiments involving re-expression of Syk in Syk-low KRAS-independent 
cell lines results in a more differentiated phenotype and inhibition of invasion and 
anchorage-independent growth[40]. It is believed that Syk inhibits the matrix 
metalloproteinase-2 (MMP2) axis, a pathway necessary for invasion and metastasis. Syk 
plays a role in preventing EMT, which is a major determinant of tumor metastasis[41]. 
Clearly, Syk has a complex role in activating or suppressing tumor progression 
depending on the molecular subtype of PDAC. 
 
Drug Synergy  
Combining multiple chemotherapeutic drugs provides a promising opportunity 
to solve the issue of drug resistance in cancer. Drug combinations can be additive, 
antagonistic, synergistic, or have no effect. Two drugs are considered additive if the 
combined effect is greater than the effect of either compound on its own.  Drugs are 
generally considered synergistic if the combined effect is greater than the expected 
additive effect of the compounds[42]. The level of synergy, or antagonism, is typically 
quantified by comparing the results of a combinational drug screen to an expected 
effect generated by a given model[43]. There is no consensus among pharmacologists on 
how synergy should be quantified. The four most widely used models are: Loewe, Bliss, 
Zero interaction potency (ZIP), and highest single agent (HSA).  HSA is perhaps the most 
simplistic of the models. As the name implies the HSA threshold for synergy is defined as 
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an effect greater than the effect of the most potent drug acting alone. The Loewe 
additivity threshold for synergy is defined as an effect greater than the effect of 
combining a single drug with itself. The Bliss model of independence assumes that each 
drug works independently of the other and the expected effect reflects the probability 
of the concurrence of each event. The ZIP model compares the difference of the IC50 
curves of each single agent to the IC50 of the drug combination[42,43]. In all four models, 
positive deviation from the expected value indicates synergy, while negative deviation 




AIMS AND OBJECTIVES 
Main Goal:  To better understand the role of Spleen tyrosine kinase in pancreatic cancer 
and the autophagy pathway.  
Aims:  
1. Identify compounds that act synergistically with the Syk inhibitor, PRT062607 
(Syki), to produce an enhanced apoptotic effect  
2.  Evaluate the effects of these drug combinations on the autophagy pathway 
3.  Narrow down the list of compounds shown to act synergistically with Syki based 
on the criteria of synergy score and live cell imaging assays 
4. Elucidate the mechanism of action of compounds from the short list and study 













MATERIALS AND METHODS  
 
Cell Lines and Maintenance  
A majority of the experiments conducted were on the KP1N and DAN-G cell lines. 
In later experiments, YAPC and PATU8898T cell lines were also used. All cell lines were 
purchased through the American Type Culture Collection. The cells were grown in 
Corning 60 mm cell culture dishes and 10 mL of RPMI 1640 (from Gibco) with the 
addition of 5% fetal bovine serum, 1 mM sodium pyruvate, and streptomycin. The cells 
were kept in the incubator at 37 degrees Celsius and 5.0% CO2.  
Roughly every five days the cells were trypsinized and re-plated at 1/5th of their 




Previously, members of our lab collaborated with Novartis to screen for 
compounds that act synergistically with the Syk inhibitor (PRT062607). They screened 
more than 46,000 compounds and determined that 1,488 compounds met the criteria 
for synergy. Of these compounds Novartis was able to send us 15. In this study the 





Compound # PubChem CID Chemical Name 
1 6223 Gliotoxin 
2 443838 Benzo[b]phenanthridine-7,12-dione, 1,8-dihydroxy-3-methyl- 
3 135474257 Collismycin A 






6 122802 Cinerubine A 
7 23642227 Onx-0914 (PR-957) 
8 11249932 TMC353121 
9 9853559 MK-0429 
10 135482271 Collismycin B 
11 5033 Radiciol 
12 9958520 Chlamydocin 
13 3477 Aspergillin 
14 97131 6-Methylpurine-beta-D-ribonucleoside 
15 265237 Withaferin A 
 
 
384-well Drug Screen 
The cells were trypsinized and resuspended in 1 mL of RPMI. Using either the 
cytation imaging machine or a hemocytometer, the cells were counted to determine 
density. The cell suspension was then diluted to the proper 384 well plating density 
using additional RPMI. The DAN-G cells were plated at a density of 31,300 cell/mL and 
the KP1N were plated at a density of 21,910. The different plating densities are 
somewhat arbitrary, however, reflect the difference in growth rate between these two 
cell lines. The Opentrons OT-2 lab robot was used to dispense the dilute cell suspension 
into 384 well plates (30 µL per well, 11.52 mL total per plate). Experiments were usually 
Figure 3: Compound Names and PubChem ID  
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conducted using 3 plates for both KP1N and DAN-G (6 plates total). The cells were then 
placed in the incubator overnight.  
24 hours later, the OT-2 lab robot was used to dispense 10 µL of Syki + serum 
free RPMI and 10 µL of unknown drug solution to each well. The concentration of Syki 
varied along the X-axis of the plate, with concentrations 0, 0.3125, 0.625, 1.25, 2.5, 5  
µM. Each unknown compound was added to half of the plate, allowing for two 
compounds to be tested per plate. The unknown compounds varied along the Y-axis of 
the plate, starting at 0 µM and generally ending at 5 µM. A six step two-fold dilution was 
used to obtain the different concentrations of the drugs. The plates were then 







Figure 4: 384-well Drug Screen Plate Layout  
 
The figure above shows the layout of the 384-well plate for the drug screen. Drug X 
and Y in the figure represent unknown compounds. Each concentration was 
administered as a quadruplicate.  
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 After 72 hours of drug treatment the cells were fixed and stained for imaging. 
The fix and stain mixture contained formaldehyde, deionized water, 10% phosphate 
buffer solution (PBS), Hoechst 33342, and LysoTracker Red. The Opentrons OT-2 lab 
robot was used to dispense 50 µL of the fix and stain mixture to each well. The plates 
were then scanned one at a time in the cytation imaging machine. Cell and lysosome 
count data were recorded.  
 
Live Imaging Assay 
 Previously, members of our lab introduced dual fluorescent LC3 to the DAN-G 
and KP1N cell lines using retroviral transduction. The chimeric LC3 protein contains 
mCherry (a red fluorescent protein) and Green Fluorescent Protein (GFP) on its N-
terminal Domain[44]. When the phagophore is formed diffuse LC3-mCherry-GFP 
aggregates and produces a yellow fluorescent signal. When the autophagosome fuses 
with the lysosome the green signal is quenched by the low pH, but the red signal 
persists. When the autophagy pathway is active the yellow signal gives way to a strong 






For the live imaging assays both cell lines were plated at a density of 100,000 cell 
per mL in a Corning 24 well plate. The cells were grown and plated in non-fluorescing 
media, FluoroBrite DMEM (from Gibco). 5% fetal bovine serum, 1 mM sodium pyruvate, 
and streptomycin were added to the media. The cells were incubated for 24 hours at 37 
degrees Celsius and 5% CO2 after being added to the 24 well plate.  
The following day 25 µL of the test compounds suspended in DMSO and 
FluoroBrite was added to each well. There were three replicates for each of the six test 
compounds, and two replicates of each of the controls (DMSO, Syki, and Chloroquine). 
The plates were then put into the cytation imaging machine. The cytation machine take 
images when the experiment begins, and then once per hour for 18 hours.  
Figure 5: LC3-mCherry-GFP 
The figure above shows the fluorescents of the chimeric LC3 protein at different 









DAN-G mCherry GFP LC3 cells were plated in a 6-well plate at a density of 50,000 
cells per mL. After 24 hours in the incubator the plate was drugged according to the 
figure at the bottom of this section (Figure 7). 24 Hours after drugging 100 uL of 1x 
Laemmli buffer with Pierce phosphatase inhibitor and Halt protease inhibitor was added 
to each well in order to lyse the cells.  The lysates were sonicated and normalized using 
the Pierce BCA protein assay. The lysates were then added to SDS and boiled to allow 
for protein denaturation. Lysates were separated using SDS-PAGE and transferred onto 
a polyvinylidene fluoride (PVDF) membrane. Syngene G-Box ECL based imaging system 
was used to capture images. The primary antibodies used include: PARP, pS6K, S6K, 
pULK, ULK, and Syk.  
 
Figure 6: 24-well Plate Layout 18 Hour Live Cell Imaging 





384-well Drug Screen Data 
The first step of this study was to validate the results of the Novartis screen and 
narrow the list of compounds down to six for further study. To do this we utilized the 
384 well Drug screen assay described in the methods section of this paper. For each 
compound cell count and lysosome count data was collected. As previously stated, there 
were four replicates of each eight concentrations of compound plus Syki. The average of 
the control well (0 uM compound + 0 uM Syki) quadruplicates was designated as 100% 
cell viability. To transform the data into the format used by the SynergyFinder (version 
2.0) software each quadruplicate was averaged and then divided by the average cell 
count of the control wells. Thus, each combination was represented as a fraction of the 
maximal cell viability. The reformatted data was then input to the SynergyFinder 









Synergy scores were generated for all 15 compounds in both cell lines. The table 
above shows synergy data for only the 6 compounds that were selected. Drugs 9, 11, 13, 
and 14 were selected because of their strong synergy scores in one or both cell lines. 
Compounds 4 and 8 were selected because they showed mild synergy with Syki in the 
DAN-G cell line and had interesting effects on normalized lysosome count in the 384 
well screen. Qualitatively, compound 4 showed a strong dose-dependent increase in 
normalized lysosome count in DAN-G cells. Conversely, drug 8 showed a dose-
dependent decrease in normalized lysosome count.  
Ultimately compounds 4 and 9 were selected for the most in depth investigation. While 
we collected the following data for all of the compounds in the 384 well drug screen, 
Figure 8: Synergy Scores  
The Table above shows the synergy Scores for the six drugs that were selected for 
further study. The left side of the table shows the results in the DAN-G cell line. The 
right side of the table shows the results in the KP1N cell line. 
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Live Cell Imaging Data 
 
Compounds 4, 8, 9, 11, 13, and 14 were used in the live cell imaging assay 
described in the methods section. The Gen5 software is able to calculate the number of 
autophagosomes by quantifying the number of yellow puncta at each time point. The 
number of red dots (without the presence of green dots) represents the number of 
autolysosomes. The ratio of autolysosomes: autophagosomes is a useful way to 
represent autophagy activation in this assay.  
Figure 9 384-well Drug Screen Compounds 4 and 9 DAN-G and KP1N 
The graphs above show the results from the 384 well drug screen as percent cell 
viability. The concentration of the test compound is shown on the x-axis. As the 







 Syki strongly activates autophagy in DAN-G cells, which have high Syk expression. 
The Syk inhibitor still activates autophagy in KP1N cells, but to a lesser extent. The cells 
treated with Chloroquine showed no increase in autolysosome: autophagosome ratio 
throughout the assay. This is because chloroquine blocks fusion of autophagosomes 
with the lysosome.  The data from this assay indicate that compound 4 activates the 
autophagy pathway in both cell lines. While the degree of activation is much more 
significant in DAN-G than in KP1N, there is clear activation in both cell lines. The effect 




Figure 10: Autolysosome: Autophagosome vs. Time (DAN-G and KP1N) 
The figure above shows the ratio of autolysosomes to autophagosomes at each 
hour during the 18 hour assay. All of the curves were fit to a 3rd order polynomial 




 Using the DAN-G mCherry GFP LC3 cell line five western blots were done to 
determine the effects of compound 4 on the mTORC1 pathway. To do this we evaluated 
the phosphorylation state of two key downstream targets of mTORC1: ULK1 and S6K. 









 As expected, the cells treated with 5.0 uM Syki and drug 4 show no 
phosphorylation of both S6K and ULK1 regardless of the concentration of compound 4. 
ULK1 and S6K are directly phosphorylated by mTORC1. Inhibition of Syk causes 
decreased mTORC1 activity, and therefor decreased phosphorylation of these 
downstream targets.  
Figure 11: DAN-G mCherry GFP LC3 Western Blot  
This figure shows the results of the wester blot experiments. The three lanes 
on the left were treated with DMSO (control) and various concentrations of 




 Interestingly, the cells treated with drug 4 on its own show no change in 
phosphorylation of ULK1 and SK6 when compared to the DMSO control. This implies 
that the drug 4 is not impacting the mTORC1 pathway. As the live cell imaging data 
(Figure 10) shows, drug 4 is a potent activator of autophagy. However, based on the 
western blot data, it is not activating the autophagy pathway via ULK1-Beclin1 
mechanism seen under conditions of mTORC1 inhibition. Clearly, the compound 4 is 
activating the autophagy pathway by a mechanism distinct from mTORC1.  
 The last point of interest from the western blot is the PARP data. PARP is cleaved 
by caspase and is a classic marker of apoptotic cell death. The cells treated with 5.0 uM 
Syki and drug 4 show significant PARP cleavage, implying that the drug combination is 
killing the cells through apoptosis. Interestingly, the cells treated with drug 4 alone show 
much less PARP cleavage, indicating that cell death is not the result of apoptosis. It will 
require further research to determine the mechanism through which drug 4 causes cell 



















Drug 4 is a high-affinity iron-chelating compound known as Nocardimicin F. This 
molecule belongs to a group of compounds called siderophores, which are produced by 
bacteria and other microorganisms to bind and transport Fe3+ across membranes. In 
mammalian cells iron is necessary for several vital processes such as DNA replication. It 
is also an important co-factor for various crucial enzymes such as cytochrome c. Cancer 
cells have a higher demand for iron than normal cells, and thus tend to over express the 
transferrin receptor[45]. Iron concentration within a cell must be tightly regulated 
because excess iron results in the formation of reactive oxygen species (ROS). Ferritin 
helps to maintain intracellular iron in the proper range by binding and storing it in a 
non-redox reactive state. Autolysosomes are responsible for the degradation of ferritin 
and other iron-containing proteins and organelles. Thus, autophagy represents an 
important mechanism through which cells maintain iron homeostasis.  
A recent study showed that the iron chelator di-2-pyridylketone 4,4-dimethyl-3-
thiosemicarbazone (Dp44mT) increases LC3 expression and autophagosome formation 
in pancreatic cancer cells[46]. Another study found that the iron chelators deferasirox 
(DFX) and deferoxamine (DFO) were able to induce cell death through an autophagy 
mediated mechanism in myeloma cells[45].The researchers found no activation of 
caspase-9 and caspase-8 in cells treated with DFX and DFO. To confirm that autophagy, 
and not apoptosis, is responsible for the cytotoxicity of these chelators the researchers 
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treated cells with the autophagy inhibitor 3-methyladenine. Indeed, inhibition of 
autophagy drastically reduced the cytotoxic effects of DFX and DFO. When the chelators 
were saturated with iron before being added to the cells the results showed reduced 
cytotoxicity and reduced phosphorylation of downstream targets of mTOR. 
Furthermore, addition of iron-chelating agents does not result in increased activation of 
AMPK. These results suggest that iron deficiency induced by chelating agents results in 
cell death via an autophagy mediated mechanism.  
Autophagy-dependent cell death has been confirmed in multiple biological 
systems, such as midgut development in Drosophila. While autophagy is generally active 
during other cell death pathways, such as apoptosis, autophagy-dependent cell death 
does not include any markers of the canonical pathways. Cells undergoing autophagy-
dependent death, also called autosis, show enhanced cell-substrate adherence, nuclear 
membrane convolution, and fragmentation of the ER. While the mechanism of autosis 
remains to be elucidated,  it is clear that the pathway is dependent on the Na+/K+-
ATPase. Autosis is prevented through pharmacological inhibition of Na+/K+-ATPase.  
The results of the PARP antibody western blot suggest that the cytotoxic effect 
of Nocardimicin F is not a result of apoptosis, and the live cell imaging data show strong 
activation of autophagy. It is possible that NCF is causing cell death via autosis. Our 
western blot data suggest that NCF is not affecting mTORC1, a result that is inconsistent 
with the study mentioned about.  There are two follow up experiments that could be 
used to determine if autophagy-dependent cell death is occurring. First, it would be 
35 
interesting to saturate the NFC with iron before drugging the cells. If the iron-chelating 
ability of NCF is in fact responsible for the cytotoxicity, then treatment with iron should 
cause a reduced effect. Second, cells should be treated with NCF and a Na+/K+-ATPase 
inhibitor. If autosis is the mechanism of cell death, a Na+/K+-ATPase inhibitor would 
prevent cell death.  
The role of autophagy and autosis in PDAC is poorly understood. It is apparent 
that autophagy can be both helpful and harmful to cancer cells depending on the 
context. Clearly, there are multiple mechanisms through which autophagy can be 
activated, and thus multiple ways in which the pathway can be targeted. Syki targets the 
autophagy pathway through the inhibition of mTORC1. Elucidation of the autosis 
mechanism will reveal novel targets for effecting the autophagy pathway. This will open 
the door to new combinational therapies to treat this devastating disease.  
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SEARCH STRATEGY 
The primary search engine used to find articles was google scholar. Initially, I 
searched for terms such as “Syk” and “KRAS”. By reading these articles I was able to find 
gaps in my own knowledge, as well as logical other topics to include. I found the 
majority of resources by reading papers cited in articles from my initial search, like 
following a bread crumb trail. If I came across a pathway or concept I am unfamiliar with 
I would search that term specifically in google scholar.  
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